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Abstract
Introduction: Consequences of lack of viral monitoring in predicting the effects of development of HIV drug resistance
mutations during HAART in resource-limited settings (RLS) is still a matter of debate.
Design: To assess, among HIV+ patients receiving their first-line HAART, prevalence of virological failure and genotypic
resistance mutations pattern in a Médécins Sans Frontières/Ministry of Health programme in Busia District (Kenya).
Methods: Patients with HAART treatment for $12 months were eligible for the study and those with HIV-RNA
$5000 copies/ml underwent genotypic study. Total HIV-1 RNA from Dried Blood Spots was extracted using Nuclisens
method.
Results: 926 patients were included. Among 274 (29.6%) patients with detectable viral load, 55 (5.9%) experienced
treatment failure (viral load .5.000 copies/ml); 61.8% were female and 10 (18.2%) had clinical failure. Median CD4 cell count
was 116 cell/mm3 (IQR: 54–189). Median HIV-RNA was 32,000 copies/ml (IQR: 11000–68000). Eighteen out of 55 (33%)
samples could be sequenced on PR and RT genes, with resistance associated mutations (RAMs) in 15 out of 18 samples
(83%). Among patients carrying RAMs, 12/15 (81%) harboured RAMs associated to thymidine analogues (TAMs). All of them
(100%) showed M184V resistance associated mutation to lamivudine as well as NNRTI’s RAMS.
Conclusions: Virological failure rate in resource-limited settings are similar to those observed in developed countries.
Resistance mutation patterns were concordant with HAART received by failing patients. Long term detectable viral load
confers greater probability of developing resistance and as a consequence, making difficult to find out a cost-effective
subsequent treatment regimen.
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Early virological failure on a nucleoside reverse transcriptase
inhibitor (NRTI) and nonnucleoside reverse transcriptase inhibitor
(NNRTI) regimen is associated with emergence of the M184V
mutation and an NNRTI resistance mutation in approximately
50–75% of patients in resource-rich settings [1,2,3].
Continuation of a failing regimen may be associated with more
complex mutation patterns, as has been observed in several studies
in developing countries [4,5,6,7,8]. The number and pattern of
resistance mutations may depend on the exact components of the
regimen, HIV-1 subtype [9,10] and the duration of failure.
Substantial NRTI resistance may occur, making empiric selection
of second-line NRTI difficult.
Sub-Saharan Africa need to face major challenges to the scaling
up of treatment programs such is scarcity in financial and human
resources and inadequate health-care infrastructure. Models of
care must be adapted to these circumstances, accounting for the
few trained health personnel, different groups of patients
compared with high-income countries (increased proportions of
children and women of child-bearing age affected), restricted drug
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availability and procurement, inadequate access to monitoring
equipment, and few extra funds.
Scaling up antiretroviral (ARV) therapy in RLS requires a
simplified approach. Because of inadequate laboratory capacity,
many programs have minimized laboratory monitoring in an
effort to accelerate widespread availability of HIV treatment [11].
However, is no longer valid the topic saying that majority of HIV-
infected people are still unable to access treatment and that
resources should be applied to prevention measures and to the
initiation of treatment, rather than to performance of expensive
laboratory tests used to monitor patients who are already receiving
treatment. Continuous expansion of HIV-infected people receiv-
ing ARV therapy in RLS increases the need to detect cases in
which first-line treatment has failed. As the need for viral load
testing increases, technologies to determine the viral load are
becoming simpler, and costs are decreasing. Thus, question of
whether high-quality, effective HIV care can be provided without
viral load monitoring needs to be revisited.
If one of the main issues that remain still a matter of debate in
low and middle income countries is the suitability for using viral
load monitoring, does it make sense to use it in order to predict
development of resistance mutations to HAART?
The aim of the study was to assess, among HIV+ patients
receiving their first-line HAART and with virological failure (viral
load .5.000 copies/ml), the prevalence of genotypic resistance
mutations and their pattern. Technology used was dried blood




Médécins sans Frontieres Spain (MSF-S) has provided ARV
treatment since July 2003 in Busia District Hospital, in the western
region of Kenya (Western province). Busia has a population of
approximately 430,000 and HIV prevalence of 5.9% (age 15–
49 years). After a period of expansion and scale-up of patient
numbers, the project focused on strengthening the care and
treatment of patients, having started around 3.500 patients on
treatment at district level and rural level through decentralised
provision of care by December 2008.
Study population
The first-line regimen in Kenya when this study was performed
consisted in stavudine (d4T), lamivudine (3TC), and nevirapine
(NVP). In the event of toxicity, one can substitute zidovudine
(ZDV) for d4T or efavirenz (EFV) for NVP, using TDF/3TC or
abacavir (ABC)/didanosine (DDI) for patients failing first-line
treatment [12].
In April 2008, all the adult ART-naı̈ve patients receiving a triple
ARV therapy regimen classified as standard first-line (e.g. D4T or
AZT, 3TC and either NVP or EFV) for 12 months or more, who
had attended the clinic at least once within the previous 6 months,
and had given informed consent to participate, were considered
for the study. The most widely ATR drug used is TriomuneR, a
fixed-dose formulation containing a combination of 2 nucleoside
reverse transcriptase inhibitors (stavudine and lamivudine) with
the non-nucleoside reverse transcriptase inhibitor nevirapine.
Triomune can be taken twice daily, irrespective of food.
As of mid-April 2008 there were 1037 adult, active, previously
treatment-naı̈ve patients who were receiving standard fist line
ARV for more than 12 months at start of study period in Busia
program. Non-naı̈ve patients as well as those treated with any
other ARV regimen were excluded from the study.
Ethical approval
This study was approved by the Ethical Review Board of
Médecins Sans Frontières and the Kenya National Ethical Review
Committee in KEMRI (Kenya Medical Research Institute).
Written inform consent was not obtained because the majority
of local people participating in this study were illiterate. Therefore,
and after a thorough explanation of the study purposes, and in
presence of a third person (family related if possible or health care
worker instead), we requested to all participants to acknowledge
their verbal informed consent. Ethical Review Board of Médecins
Sans Frontières as well as Kenya National Ethical Review
Committee in KEMRI (Kenya Medical Research Institute)
approved this consent procedure.
Laboratory procedures
On the day of enrolment, a venous blood sample of 10 mL was
taken and divided into two parts: one had a CD4 count done at
the Busia lab using the FASCOUNT machine using the
manufacturer’s guidelines, and the other one was sent to Kenya
Research Institute Nairobi (KEMRI) in a plasma preparation tube
where viral load testing was done using the NucliSENS EasyQ
HIV equipment, version 1.2, using the manufacturer’s guidelines,
with limit of detection of 50 copies/ml.
Patients having a viral load .5.000 copies/ml provided an
additional sample for preparation in dried blood spot (DBS)
[13,14]. Even though viral load .1.000 copies/ml would be
enough to perform genotyping, we decided to select patients with
.5.000 copies/ml for two main reasons: the lower sensitivity of
genotype testing using Dried Blood Spots Filter Papers and the fact
that due to technical constraints, that is, inability to keep cold
chain during the whole transportation process, we used BD
Vacutainer PPT Plasma Preparation tubes (PPT) (Becton Dick-
inson and Company, Franklin Lakes, NJ). Several studies have
reported that the use of Vacutainer plasma preparation tubes
(PPTs) to transport plasma specimens have consistently yielded
higher HIV RNA levels than EDTA tubes [15,16,17,18].
Fifty microlitres of whole blood and plasma were used to make
each spot respectively. These were dried overnight on special
drying racks, packed and sent to the Research Laboratory from
Hospital Universitari MutuaTerrassa, in Barcelona, for HIV
resistance genotyping tests. Before study initiation, training was
implemented among technicians (local staff) responsible of
sampling procedure.
Self report adherence questionnaire
Adherence was measured using a simple questionnaire trans-
lated to the local language. The questions were structured based
on the WHO adherence criteria. Pill counts for the patients were
done by adherence counsellors.
Definition of treatment and virological failure
For the purpose of our study we performed a viral load test for
all patients that were enrolled in the study. Samples with viral
loads $5.000 copies/ml were selected for genotype testing.
Treatment failure
Treatment failure based on CD4 test criteria was defined as
either a CD4 below the baseline or less than 50% of peak at
12 months or CD4 ,100 cells/mm3 after 12 months of therapy.
Treatment failure based on clinical criteria was defined as the
occurrence of either a new or a recurrent disease defining WHO 3
or stage 4 at 12 months from the start of medication [19].
HIV Viral Load in Resource Limited Settings
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Virological failure
Currently, WHO defines virological failure as plasma HIV-1
RNA level .5.000 copies/ml after 6 months of treatment.
However, at the time of the study (2008) the programme was
following WHO 2006 recommendations where the cut-off for
virological failure was .10.000 copies/ml,. Notwithstanding, in
our study the aim was to assess the level of HIV drug resistance
mutations and to describe and rank specific HIV-Drug Resistance
mutations and mutation patterns among patients not achieving
virological suppression. Therefore, all patients with VL .5.000
had their sample collected for genotype testing.
Sample collection and shipment
Patients having a viral load $5.000 copies/ml provided an
additional blood sample to prepare dried blood (DBS-FP) on
Schleicher and Schuell 903 filter paper to send to Hospital
Universitari MutuaTerrassa, AIDS research Unit, in Terrassa, for
genotyping test. The BD PPTTM tubes (plasma preparation tubes)
were used to separate plasma, following the manufacturer’s
instructions. Briefly, 5 ml of whole blood were collected into the
PPTTM tubes using universal phlebotomy practices, and briefly
gently inverted to mix. Of this sample, 400 ul were spoted on the
filter paper in the 5 pre-marked circles (50 ul each). The remaining
sample was centrifuged at 3000 rpm for 10 minutes to obtain
plasma. This plasma was collected into vacutainer tubes for viral
load assay. Filter papers were leaved to dry on drying racks
overnight in a horizontal position at a room temperature. They
were then packed in glycine envelopes with desiccants to keep
them dry and shipped to the genotyping laboratory in Barcelona
following the laid down procedures for sample packaging and
shipment. Samples were kept during the whole procedure and
transportation at room temperature. In our laboratory, total HIV-
1 RNA from DBS was extracted using Nuclisens method
(Easymag, Biomerieux). A unique fragment of 1023 bp of pol
gene containing the major part of PR and RT was amplified using
in-house RT-PCR and nested PCR previously described in the
literature [13].
Genotyping was validated using the ViroScore Suite (ABL,
Luxembourg, v3.9.2).
Statistical analysis
Qualitative and quantitative variables were described using
percentages and 95% confidence intervals (CI), means and
standard deviation or median and interquartile ranges (IQR),
depending upon distribution was normal or not. Comparisons
between patients with or without virological failure were examined
using Pearson’s chi square test or Fisher’s exact test for qualitative
variables and t-test or U Mann-Whitney test for quantitative
variables. Previously, Levene test was performed to determine
homogeneity of variance.
In addition, proportion comparison test for independent
samples through Z statistic were performed for comparison of
adherence results.
P values less than 0.05 were considered statistically significant.
Analyses were conducted using the statistical package StataSE
vs9.0 (Stata Corporation, College Station, Texas, USA).
Results
Among 1037 recruited patients under HAART during
$12 months, 926 were included in the analysis (Figure 1). Out
of 111 non-included patients only 8 (7.2%) were non-responders
Figure 1. Patient’s disposition.
doi:10.1371/journal.pone.0047391.g001
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and 4 died, the remaining patients were lost of follow-up, or have
an exclusion criteria. Mean time on ARVs were 38.8 months
(range: 17.0–60.0) and patients mean age were 42.1 y. (range:
18,6–73,1), with a higher proportion of females (67.3%) (Table 1).
Among the whole population studied, 274 patients (29,7%, 95%
CI: 13.6–18.4) had detectable viral load ($50 copies/ml) and 55
(5.9%, 95% CI: 4.4–7.5) had a viral load $5.000 copies/ml, thus
underwent genotypic study. Among 55 patients of genotypic study,
mean age was 37.9 years (range: 18.7–72.5) and 34 (61.8%) were
females. Only 10 out of 55 patients (18.2%) experienced clinical
failure, (treatment failure based on clinical criteria) defined as the
occurrence of either a new or a recurrent disease defining WHO 3
or stage 4 at 12 months from the start of medication. The median
CD4 cell count and HIV RNA were 116 cell/mm3 [interquartile
range (IQR) 54–189] and 32,000 copies/ml respectively (IQR:
11.000–68.000) (table 1). ART regimen started at time of inclusion
were d4T/3TC/NVP in 53 (96.4%) and AZT/3TC/NVP in 2
patients (3.6%). Regarding mean time on HAART, there were no
significant statistical differences between patients that had
virological failure (n = 55) and those patients (n = 871) who did
not (mean: 40,1 vs. 38,7 months respectively).
Of the 55 samples, only 18 (33%) could be amplified and
evaluated by genotyping. Based on Stanford University HIV Drug
Resistance Database, we inferred subtypes from entering FASTA
sequence information: the majority of samples were subtype A
(13/18; 72,2%), subtype D (4/18; 22,2%) and G (1/18; 5,6%).
Among 18 samples sequenced on PR and RT genes, 15 out of
18 (83.3%, 95% CI: 58.6–96.4) showed RT resistance associated
mutations (RAMs). The median number of resistance mutations
(any class) was 5 (IQR: 2,75–6). Three samples had no mutations
identified (table 2).
Fifteen out of 18 patients (83.3%) carried NNRTI resistance
associated mutations, although there were no patients with only
NNRTI mutations. The median number of NNRTI mutations
was 1 (IQR: 1–2). The most frequent NNRTI mutations were
K103N/S (27.8%), followed by Y181C (22.2%), V108I and
G190A (16.7%), Y181V (11.1%), K101E and Y188L (5.6%)
(Figure 2).
Prevalence of NRTI resistance associated mutations are
depicted in Figure 3. The M184V mutation was present in virus
from 15 patients (83.3%), although never as the only mutation.
Four patients (22.2%) carried virus with only M184V and NNRTI
mutations (Table 3). The most common mutation pattern was
M184V and NNRTI mutations with one or more TAMs, which
occurred in 12 (66.7%) patients.
Among patients carrying RAMs, 12/15 (80.0%) harboured
RAMs associated to thymidine analogues (TAMs) (M41L, D67N,
K70R, V75I, L210W, T215F/Y) (Table 3). All of them (100%)
showed also M184V RAM to lamivudine. Of the patients with
TAMs containing virus, 16.7% had one, 33.3% had two, and
50.0% had three or more TAMs. The most frequent TAMs were
T215F/Y (11/12, 91.7%), M41L (10/12, 83.3%), L210W (3/12,
27,3%), D67N (3/12, 25.0%), K70R (1/12, 8.3%) and V75I (1/
12, 8.3%) (Table 3). One patient carried Q151M mutation,
associated with M41L, D67N, T215F and M184V, conferring
pan-nucleoside resistance, except to tenofovir. There were no
patients carrying either K65R or T69 insertion.
In our study all failing patients with HIV-1 RNA .5.000 cop-
ies/ml harboured TAMs. Among the three patients having
samples with no mutations identified, viral load were high (mean:
750.000 copies/ml; 5,9 logs).
According to Stanford HIV database, 10 out of 15 (66.7%)
patients were resistant to both ARV families used, that are
stavudine, zidovudine, lamivudine and nevirapine/efavirenz.
Table 1. Patients with VL .5.000 copies/ml (N = 55).
VL .5.000 copies/ml 55/926 (5,9%)
Mean age 37.9 (range:18.7–72.5)
Females 34 (61.8%)
Clinical failure 10 (18.2%)
Median CD4+ 116 cells/mm3 (IQR: 54–189)
Median VL (RNA-VIH) 32.000 copies/ml (IQR: 11.000–68.000)
ARV regimen started: d4T/3TC/NVP AZT/3TC/NVP 53 (96.4%)2 (3.6%)
Mean duration on HAART 40.1 months (range: 20–52)
doi:10.1371/journal.pone.0047391.t001
Table 2. RAMS among patients with virological failure
(VL.5.000 copies/ml) amplified and evaluated by
genotyping.
Resistance Associated Mutations (RAMs) N (%)
Some RAMs 15/18 (83.3%)
N TAMS (M41L, D67N, K70R, V75I, L210W, T215Y/F,
Q151M)
11/15 (73.3%)
N M184V 15/15 (100%)




Figure 2. NNRTI’s resistance mutations prevalence.
doi:10.1371/journal.pone.0047391.g002
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Regarding samples sequenced on protease gene, we have found
only common polymorphisms not associated with decreased PI
susceptibility. We did not find primary RAMs to protease
inhibitors (Table 3).
Adherence results
Adherence questionnaire did not discriminate among those
patients harbouring some resistance mutations and those without
any resistance at all. In contrast, 30,99% of patients having viral
load .5000 copies/ml (n = 55) vs. 44.2% of patients with viral
load ,5000 copies/ml (n = 871) reported ‘‘never missed medica-
tions’’ (p,0,05).
Discussion
Despite earlier doubts, evidence is available that even in
countries with very limited resources, ART programmes based on
the public health approach have shown effectiveness equal to that
seen in clinical cohorts in USA and Europe using similar regimens
[8,20,21,22,23,24,25,26]. Therefore, fears that HIV/AIDS treat-
ment in RLS would lead to widespread drug resistance have been
unfounded. Our study provides additional scientific concerns
about comprehensive approach to monitoring, care and treatment
management in settings in which resources are limited.
Also virological failure rate in our study is similar than those
reported so far in developed countries. Likely, results from several
Figure 3. NRTI’s resistance mutations prevalence.
doi:10.1371/journal.pone.0047391.g003
Table 3. Genotypic results.
ID HAART VL H* Protease Retrotranscriptase
2 1 63000 10% H69K, L89V K101E, M184V, G190A, T215Y
4 1 11000 10% I62V, L63P, I64V, H69Y K103N, M184V
5 1 5600 10% M36I, D60E M41L, A98G, K103N, M184V, T215Y
6 1 5700 10% H69K, L89M M41L, V75I, V90I, K103N, V179I, M184V, T215Y
8 1 1000000 10% H69Q, L89M M41L, V108I, V179I, Y181C, M184V, L210W, T215Y
10 1 140000 10% M36I, I62V, H69R, V82Y, L89M
11 1 9200 10% D60E, H69K, L89M M41L, M184V, Y188L, L210S, T215Y
13 1 910000 10% H69K, L89M V179I
19 1 6200 60% L63Q, H69Y K70R, V108I, Y181C, M184V
30 1 29000 30% M36I, I62V, L63T, I64M, H69K, L89M M41L, V75I, V179I, Y181C, M184V, T215Y
31 1 47000 30% M36I, H69K, L89M M41L, V179I, M184V, G190A, T215F
33 1 1200000 30% E35D, M36I, H69K, L89M
36 1 11000 30% H69K, L89M K103S, V179I, M184V
37 1 130000 30% L63P, H69K, L89M M41L, D67N, K103N, Q151M, M184V, T215F
38 1 43000 30% D60E, H69K, L89M M41L, D67N, V179I, Y181V, M184V, L210W, T215Y
39 1 68000 30% M36I, L63T, H69K, V82I, L89M, I93L K101A, V179I, M184V, G190A
46 2 170000 30% H69K, L89V, L90T M41L, D67N, Y181V, M184V, L210W, T215Y
53 1 130000 40% D60E, H69K, L89M M41L, V108I, V179I, Y181C, M184V, T215Y
N % of humidity.
N HAART: 1.-3TC/d4T/NVP; 2.-AZT/3TC/NVP.
doi:10.1371/journal.pone.0047391.t003
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operational research performed in different RLS yielded the same
results than our study, with a longer follow-up period (Table 4).
The ability to collect blood samples on filter paper represents an
advantage for HIV drug resistance surveillance and monitoring,
particularly in areas that lack the appropriate infrastructure for
plasma processing and transport. We used DBS method for
genotyping purposes due to its simplicity and the fact that filter
paper technology allows shipment with minimal biohazard risks.
One of the crucial points for the use of dried fluid spots for drug
resistance genotyping in the field is the stability of RNA over time.
Dried blood spots can be kept for long periods when refrigerated
or frozen in hermetic bags with desiccant but exposure to high
temperatures for extended periods seems to be associated with
degradation. Few studies have reported on long-term storage or
testing under field temperature conditions, and contradictory
percentage of genotyping efficiency of blood and plasma sample
collection devices such DBS results have been reported, compared
with gold standard plasma [27,28,29].
In our study, we could amplify to evaluate by genotyping only
one third of samples. Such a low percentage of positive genotypic
results among failing patients might be explained by different
factors, mainly related with the obstinate real life in Operational
Research in RLS that make difficult the optimisation of sampling
procedure: storage conditions, transportation and cold chain
preservation as it was mentioned in methods, in our study samples
were kept during the whole procedure and transportation at room
temperature. Also, combination of insufficient concentration of
viral RNA and decreased quality of RNA in DBS specimens can
explain our low PCR amplification rate. Nonetheless, in our study,
there were no statistically differences in viral load between
amplificated and non amplificated samples. McNulty et al.
demonstrated also the same rate of amplification of HIV-1 pol in
DBS among Cameroonian HIV infected people that were
stratified according different plasma viral load (from 5.000 to
.50.000 copies/ml) [30]. Moreover, although filter paper were
packed in glycine envelopes with desiccants to keep them dry,
more than half of the samples (62%) received in our research lab in
Terrassa had a humidity degree of 30% or higher, according
humidity indicators. We hypothesized that such a high humidity
degree was due, at least in part, because Busia OR study was
performed during rainy season. Contradictory results in the
literature suggest that some degradation of RNA may have
occurred during long-term storage at 48uC possibly due to
suboptimal storage temperature, humidity or both. High humidity
conditions are thought to be detrimental to resistance testing from
DBS given the extreme sensitivity of HIV nucleic acids to
degradation in the presence of humidity [14].
Although resistance mutation patterns were not available
among the whole samples sequenced, genotypic results were
concordant with ARV treatment received by failing patients,
which is either nevirapine/d4T/3TC or nevirapine/AZT/3TC
(Table 3). Resistance mutations profile allowed us to switch ART
to a second-line therapy based on a backbone of either tenofovir/
FTC or ABC/ddI with a boosted protease inhibitor (lopinavir).
The majority of samples amplified from failing patients carried out
M184V RAM (high level resistance to 3TC/FTC), NNRTI
resistance associated mutations (cross resistance to NVP and EFV),
as well as several thymidine analogue resistance mutations
(TAMS), conferring different degrees of resistance to NRTIs.
The absence of any relevant resistance mutation among three
patients probably corresponds to patients who did not take
medication at all, reinforcing the importance of treatment
adherence in the context of lack of regular access to VL
monitoring and genotype. Intensive therapeutic education, coun-
selling and psychosocial support might explain the very low rate of
lost-to follow-up patients observed, thus emphasizing that human
resources remain a key factor in resource-limited settings.
The mutations observed were those expected under the first-line
regimen used, and the great majority of patients were resistant to
nevirapine/efavirenz (100%), lamivudine (100%) and stavudine
(83%). Overall, these observations are similar to other first-line
cohort studies in RLS describing HIV-1 mutation patterns
[20,31,32], suggesting that switch after a first-line ART failure in
RLS might be feasible without a genotypic test. However, some
authors have warned about the fact that d4T-based initial therapy
in patients infected with subtype C virus selects for a broader array
of mutations, including the K65R mutation, conferring resistance
to d4T, ddI, ABC, 3TC, FTC, and TDF [10]. Subtypes profile
found in our study are very concordant with results of a
multicenter study carried out in four African cities, one of them
closer from Busia (subtype distribution in Busia and Kisumu were
72% vs. 71%, 22% vs. 20% and 5,6% vs. 2% for A, D and G
respectively) [33].
The accumulation of thymidine analogue and other resistance
mutations can confer cross-resistance to many, and possibly, to all
NRTIs that might be used in a second line-regimen. This
phenomenon may be less likely when tenofovir is included in the
first-line regimen. However, despite WHO 2010 recommenda-
tions, tenofovir is still commonly unaffordable in RLS. This data,
together with our findings showing high TAMS mutation rate in
our cohort, as well as the high rate of d4T-related polineuropathy–
data not shown-, suggest that in RLS we desperately need other
changes to make treatment more comparable to that in
industrialised countries. We should consider moving away from
d4T, rarely used in the North, to the easier tenofovir, although it
would also cost more money (tenofovir currently costs four times
more).
UNAIDS 2010 global report have included important key
elements to improve the efficiency and quality of HIV treatment
and care: a) start ARV therapy earlier, b) use less toxic and more
patient-friendly options (fixed dose combinations) and c) use of
laboratory monitoring tools such as CD4 and viral load counts.
Table 4. Virological failure rates over time in different resource limited settings.
Busia Mean Tx duration: 38,8 m. (926 patients)
Malawi2 Mean Tx duration: 9 m
(397 patients)
Cambodia3 Mean Tx duration: 24 m (346
patients)
VL.400 = 16% VL.400 = 16% VL.400 = 11.6%
VL.1000 = 10,7% VL.1000 = 13% VL.1000 = 9%
VL.30.000 = 3,0% VL.30.000 = 5.0% VL.30.000 = 4.3%
2Ferradini et al. Lancet 2006; 367:1335–42. 3 Ferradini et al. AIDS 2007, 21:2293–2301.
doi:10.1371/journal.pone.0047391.t004
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Nevertheless, introduction of safer but currently more expensive
first-line ARTs, as well as viral load monitoring, needs to be
phased-in as currently they may not be feasible or affordable in
many high-burden settings with low coverage, less developed
health systems, limited laboratory capacity, finite budgets and
competing health priorities.
Newer guidelines [34] suggest also starting one of the following
regimens in ART-naı̈ve individuals eligible for treatment: AZT +
3TC + EFV; AZT + 3TC + NVP; TDF + 3TC or FTC + EFV,
TDF + 3TC or FTC + NVP. A boosted protease inhibitor (PI/r)
plus two nucleoside analogues (ZDV, 3TC and tenofovir as a
NRTI backbone) are recommended for second-line ART, being
ATV/r and LPV/r the preferred boosted PI’s. The main objective
of these recommendations try to avoid the disfiguring, unpleasant
and potentially life threatening toxicity of d4T, the need to select
regimens suitable for use in most patient groups, and the benefits
of using fixed dose combinations. Therefore, with the increasing
need for availability of second-line regimens, there is a reasonable
argument in support of the widespread, rational use of viral load
testing. Although still expensive for RLS at present, it has the
potential to prevent unnecessary switches to expensive second line
therapies.
Although recent modelling study support little added survival
benefit to the addition of laboratory viral load monitoring
compared with clinical monitoring alone [35], not only early
survival need to be considered [36]. The long term consequences
of high viral load must be calibrated. High viral load on treatment
is associated with a greater probability of developing resistance.
Therefore, despite that, according some data, from a survival point
of view benefits from viral load monitoring might be modest, the
accumulation of resistance mutations will confer difficulties to find
a cost-effective subsequent treatment regimens, especially in
settings with limited second line options and where people will
still need decades of therapy. Moreover, the same modelling
strategy authors have demonstrated in a more recent study that to
preserve current first line drugs as widespread treatment options
for future generations, there is a long term need for introduction of
some form of cheap, practical, and sustainable viral load
monitoring in resource limited settings which can be used in rural
as well as urban settings. Also, their results indicated that even very
infrequent (e.g. 3 yearly) testing, is likely to provide significant
benefit in reducing resistance transmission [37].
In this regard, recently, some authors have presented data from
an operational research trial in Zambia, aiming to ascertain the
added value of routine viral load testing. This cluster randomized
trial of routine versus discretionary (if clinical failure criteria met)
viral load monitoring among adults starting ARV therapy,
demonstrated that routine viral load testing clearly limits the
amount of time spent on a failing regimen in RLS. Time between
virological failure and change of the regimen to second line
treatment among routine viral load testing group was 168 days
compared with 560 days among control group, thus with
substantially less time (.1 year) on a failing regimen and higher
rate of change to a second line regimen [38]. Results of the
resistance and cost-effective analysis are still pending, and they will
provide important information on the costs of that delay for future
treatment options.
Conclusion
We have long known of increased mortality in African patients
on ART compared with outcomes elsewhere. A conclusion would
seem that if the future is to be different, we have to intervene
earlier. Current worldwide expansion of ARV therapy for HIV in
resource-limited countries entails new challenges to be considered.
More than 6,5 million people are receiving ART, with the
majority of patients on treatment worldwide now being from
resource limited settings. Important treatment-related issues
identified by several scientific communities, such as when to
switch therapies, long-term consequences of virological failure
after current first ART strategy, toxicity, adherence, drug-drug
interactions or optimal treatment of pregnant women, need to be
addressed immediately.
Moreover, controversial issues about comprehensive laboratory
monitoring such as routine monitoring viral load for safety and
efficacy in these settings should be elucidated. VL testing could
increase in importance as a guide for clinical decisions on when to
switch to second-line treatment and on how to optimize the
duration of the first-line treatment regimen, minimizing the impact
of ARV resistance mutations on treatment. Therefore, now we
must pay attention to monitoring to limit the costs associated with
widespread use of expensive second-line therapy, ensuring that VL
testing becomes affordable, simple and easy to use in RLS.
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